Tokyo, Japan

Shin-ichiro Ohno

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Tokyo Medical University. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Shin-ichiro Ohno in Nucleic Acid Delivery

Introduction

Shin-ichiro Ohno is a notable inventor based in Tokyo, Japan. He has made significant contributions to the field of biotechnology, particularly in the area of nucleic acid delivery systems. His innovative work focuses on improving the methods for administering nucleic acids into cells, which has important implications for gene therapy and molecular medicine.

Latest Patents

Shin-ichiro Ohno holds a patent for a "Nucleic acid carrier and method for administering nucleic acid." This invention provides a novel carrier designed to introduce nucleic acids, such as siRNA, into cells. The carrier includes vesicles derived from plants in the family Malpighiaceae, with a preference for those obtained from acerola. The method involves forming a conjugate of the nucleic acid carrier and the nucleic acid, followed by administering this conjugate to achieve effective delivery.

Career Highlights

Ohno is affiliated with Tokyo Medical University, where he continues to advance research in biotechnology and molecular delivery systems. His work has garnered attention for its potential to enhance therapeutic strategies in treating various diseases.

Collaborations

Some of his notable coworkers include Masahiko Kuroda and Masakatsu Takanashi, who have collaborated with him on various research projects aimed at improving nucleic acid delivery methods.

Conclusion

Shin-ichiro Ohno's innovative contributions to nucleic acid delivery systems highlight the importance of advancements in biotechnology. His work not only enhances our understanding of molecular delivery but also paves the way for future therapeutic applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…